Table 1.

Characteristics of patients with SScPAH.

CharacteristicsUnmatched, n = 275Matched, n = 98Absolute Standardized Difference
No Warfarin, n = 197Warfarin, n = 78No Warfarin, n = 49Warfarin, n = 49Unmatched n = 275Matched n = 98
Female sex, n (%)165 (84)66 (85)45 (92)44 (90)0.220.07
PAH characteristics at diagnosis
  mPAP mm Hg, mean (SD)39.0 (14.3)46.8 (14.3)38.8 (15.3)42.5 (11.8)0.540.27
  WHO Functional Class III/IV, n (%)68 (35)36 (46)23 (47)23 (47)0.150
  Moderate-severe RV enlargement, n (%)25 (13)25 (32)11 (22)13 (27)0.220.05
  Moderate-severe RV hypokinesis, n (%)25 (13)25 (32)11 (22)13 (27)0.220.05
Comorbidities, n (%)
  Cancer21 (11)8 (10)7 (14)6 (12)< 0.010.02
  Coronary artery disease27 (14)7 (9)6 (12)5 (10)0.050.02
  Diabetes mellitus10 (5)7 (9)4 (8)2 (4)0.040.04
  Hyperlipidemia11 (6)9 (12)6 (12)3 (6)0.060.06
  Hypertension55 (28)16 (21)16 (33)9 (18)0.090.06
  Peripheral vascular disease9 (5)4 (5)2 (4)3 (6)0.010.02
  Ischemic stroke7 (4)2 (3)2 (4)2 (4)0.010
Concomitant medications, n (%)
  Calcium channel blocker104 (53)33 (42)23 (47)23 (47)0.140
  ER antagonist35 (18)33 (42)9 (18)15 (31)0.290.14
  PDE inhibitor16 (8)5 (6)3 (6)5 (10)0.020.04
  Prostaglandin analog10 (5)13 (17)4 (8)4 (8)0.120
  • SScPAH: systemic sclerosis-associated pulmonary arterial hypertension; mPAP: mean pulmonary artery pressure; WHO: World Health Organization; RV: right ventricular; ER: endothelin receptor; PDE: phosphodiesterase.